APA (7th ed.) Citation

Chanthavanich, P., Anderson, E., Kerdpanich, P., Bulitta, M., Kanesa-Thasan, N., & Hohenboken, M. (2019). Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects. The Pediatric infectious disease journal, 38(7), 757. https://doi.org/10.1097/INF.0000000000002345

Chicago Style (17th ed.) Citation

Chanthavanich, Pornthep, Edwin Anderson, Phirangkul Kerdpanich, Michael Bulitta, Niranjan Kanesa-Thasan, and Matthew Hohenboken. "Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects." The Pediatric Infectious Disease Journal 38, no. 7 (2019): 757. https://doi.org/10.1097/INF.0000000000002345.

MLA (9th ed.) Citation

Chanthavanich, Pornthep, et al. "Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects." The Pediatric Infectious Disease Journal, vol. 38, no. 7, 2019, p. 757, https://doi.org/10.1097/INF.0000000000002345.